Identifying potential drugs for treating Cardiovascular-kidney metabolic syndrome via reverse network pharmacology
The "two-hit" HFPEF model can be used as a new model of CKM, and BBR may become a new candidate drug for the treatment of CKM through multiple targets.
Authors
- Xin Zhong (ORCID: https://orcid.org/0000-0003-3327-1045)
- Xiuqin Hong (ORCID: https://orcid.org/0000-0002-5449-1832)
- Haoran Zhong (ORCID: https://orcid.org/0000-0003-0967-9542)
- Wen Xiao (ORCID: https://orcid.org/0000-0001-6559-3036)
- Yongjun Hu (ORCID: https://orcid.org/0000-0001-5929-6297)
- Yayu You
- Zhengyu Liu (ORCID: https://orcid.org/0000-0003-4642-5955)
- Linkai Li
- Ao-Ni Fu
- Siao Wen (ORCID: https://orcid.org/0009-0002-1314-8752)
- Fen Liu (ORCID: https://orcid.org/0009-0005-2469-7513)
Institutions
- Health and Family Planning Commission of Hunan Province (CN)
- University of South China (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.3389/fphar.2025.1627236
- Citations
- 1
- Primary Topic
- Berberine and alkaloids research
- Type
- article
- Field-Weighted Citation Impact
- 1.39